Obesity
Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy
Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk
Limited Access to Mounjaro: England’s NHS Rolls Out Obesity Drug with Phased Approach
Mounjaro, obesity drug, NHS England, limited access, phased rollout, weight loss medication, tirzepatide.
Eli Lilly Invests $3 Billion in Wisconsin Manufacturing Expansion to Meet Growing Demand for Diabetes and Obesity Medicines
Eli Lilly, Wisconsin, manufacturing expansion, diabetes, obesity, pharmaceuticals, investment, job creation
Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study
Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5
Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations
Amgen, MariTide, weight loss, obesity treatment, clinical trial results
Biden Administration Proposes Expanded Coverage of Anti-Obesity Medications for Medicare and Medicaid Enrollees
Biden Administration, Obesity Drug Coverage, Medicare, Medicaid, Prescription Drug Costs, Healthcare Reform
Biohaven’s Taldefgrobep Alfa Shifts Focus to Obesity After Missing Primary Endpoint in Spinal Muscular Atrophy Phase 3 Trial
Biohaven, taldefgrobep alfa, spinal muscular atrophy (SMA), obesity, myostatin inhibitor, phase 3 trial, body composition, lean muscle mass, bone density.
Biohaven’s Taldefgrobep Alfa Misses Primary Endpoint in Phase 3 SMA Trial, Eyes FDA Discussions and Obesity Indication
Biohaven, Taldefgrobep Alfa, Spinal Muscular Atrophy (SMA), Phase 3 Trial, FDA Discussions, Obesity Indication
Enveda Secures $130 Million in Funding for Innovative Therapies in Inflammation, Obesity, and Beyond
Enveda, Microsoft-backed, $130M funding, Inflammation & Immunology (I&I), obesity, biotech, pharma, drug development
Versant Ventures Launches Pep2Tango Therapeutics with Revolutionary Tetra-Receptor Agonist Approach for Obesity Treatment
Obesity treatment, Tetra-receptor agonist peptides, GLP-1/ GIP/ amylin/ and calcitonin receptors, Muscle mass preservation, Next-generation weight loss therapies, Versant Ventures, Pep2Tango Therapeutics Inc.